An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease

Mosaburo Kainuma1*, Shinji Ouma2, Shinobu Kawakatsu3, Osamu Iritani4, Ken-Ichiro Yamashita5, Tomoyuki Ohara6, Shigeki Hirano7, Shiro Suda8, Tadanori Hamano9, Sotaro Hieda10, Masaaki Yasui11, Aoi Yoshiiwa12, Seiji Shiota12, Masaya Hironishi13, Kenji Wada-Isoe14, Daiki Sasabayashi15, Sho Yamashita15, Masayuki Murata16, Kouta Funakoshi17, Kouji Hayashi18, Norimichi Shirafuji9, Hirohito Sasaki9, Yoshinori Kajimoto13, Yukiko Mori10, Michio Suzuki15, Hidefumi Ito11, Kenjiro Ono10,19 and Yoshio Tsuboi2

1Department of Japanese Oriental Medicine, Toyama University Hospital, Toyama, Japan, 2Department of Neurology, School of Medicine, Fukuoka University, Fukuoka, Japan, 3Department of Neuropsychiatry, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan, 4Department of Geriatric Medicine, Kanazawa Medical University, Kanazawa, Ishikawa, Japan, 5Translational Neuroscience Center, Graduate School of Medicine, International University of Health and Welfare, Tochigi, Japan, 6Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 7Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan, 8Department of Psychiatry, Jichi Medical University, Tochigi, Japan, 9Division of Neurology, Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan, 10Division of Neurology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 11Department of Neurology, Wakayama Medical University, Wakayama, Japan, 12Department of General Medicine, Oita University Faculty of Medicine, Oita, Japan, 13Department of Internal Medicine, Wakayama Medical University Kihoku Hospital, Wakayama, Japan, 14Department of Dementia Medicine, Kawasaki Medical School, Okayama, Japan, 15Department of Neuropsychiatry, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, 16Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan, 17Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan, 18Department of Rehabilitation, Fukui Health Science University, Fukui, Japan, 19Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan

Background: Alzheimer’s disease (AD) is a progressive neurodegeneration and is the most prevalent form of dementia. Intervention at an early stage is imperative. Although three acetylcholinesterase inhibitors (AChEIs) are currently approved for the treatment of mild AD, they are not sufficiently effective. Novel treatments for mild AD are of utmost importance.

Abbreviations: AChEI, acetylcholinesterase inhibitor; AD, Alzheimer’s disease; ADAS–Cog, Alzheimer’s disease assessment Scale–cognitive component–Japanese version; AEs, all adverse events; CREB, cAMP response element binding protein; FAS, full analysis set; HJC, Hachimijiogan; IADL, instrumental activity of daily Life; MCID, minimally-clinically important difference; MMSE, mini mental state Examination; NPI, neuropsychiatric inventory; PPS, per protocol set; PS, RED Cap, Research electronic data capture; SAS, safety analysis set.
Objective: To assess the effectiveness of hachimijiogan (HJG), a traditional Japanese herbal medicine (Kampo), in the treatment of mild AD.

Methods: This exploratory, open-label, randomized, multicenter trial enrolled patients with mild AD whose score on the Mini Mental State Examination (MMSE) was over 21 points. All participants had been taking the same dosage of AChEI for more than 3 months. The participants were randomly assigned to an HJG group taking HJG extract 7.5 g/day in addition to AChEI or to a control group treated only with AChEI. The primary outcome was the change from baseline to 6 months post treatment initiation on the Alzheimer’s Disease Assessment Scale-cognitive component- Japanese version (ADAS-Jcog). The secondary outcomes were change from baseline of the Instrumental Activity of Daily Life (IADL), Apathy scale, and Neuropsychiatric Inventory (NPI) -Q score.

Results: Among the 77 enrollees, the data of 69 (34 HJG and 35 control) were available for analysis. The difference in the change of ADAS-Jcog from baseline to 6 months of the HJG and control groups was 1.29 (90% Confidence interval (CI), −0.74 to 3.32, p = 0.293). In the subgroup analysis, the differences in the change from baseline to 3 and 6 months for women were 3.70 (90% CI ,0.50 to 6.91, p = 0.059) and 2.90 (90% CI,0.09 to 5.71, p = 0.090), respectively. For patients over 65 years, the difference at 3 months was 2.35 (90%CI, 0.01 to 4.68 p = 0.099). No significant differences were found between the HJG and control groups in IADL score, Apathy scale, or NPI-Q score.

Conclusion: Although not conclusive, our data indicate that HJG has an adjuvant effect for acetylcholinesterase inhibitors and that it delays the deterioration of the cognitive dysfunction of mild Alzheimer’s disease patients.

Clinical Trial Registration: http://clinicaltrials.gov Japan Registry of clinical trials, identifier jRCTs 071190018

KEYWORDS
Alzheimer’s disease, hachimijiogan, ADAS-Jcog, Kampo medicine, cognitive dysfunction

Introduction

Cognitive and memory impairment in Dementia leads to negative changes in behavior and activities of daily life (Cipriani et al., 2020). More than 35 million people worldwide currently suffer from dementia, with an incidence of about 10 million each year. Estimates indicate it will rise to 78 million in 2030 and 139 million in 2050. Alzheimer’s disease (AD) is the most prevalent form of dementia, accounting for 60–70% of the disease (World health Organization, 2018).

Currently, AD is considered to start decades before clinical symptoms occur, and it is classified into three phases: preclinical AD, mild cognitive impairment (MCI) due to AD, and AD dementia (Sperling et al., 2011). Observational studies have reported associations between several vascular and lifestyle-related risk factors and increased risk of late-life cognitive impairment and AD, the most prevalent form of dementia (Norton et al., 2014). It is imperative that we focus on prevention of AD (prevention from the preclinical stage) and secondary prevention (intervention from MCI due to AD: early detection, early diagnosis, and early treatment) (McDade and Bateman., 2017). Numerous drug and non-drug therapies have been developed with the goal of alleviating or curing symptoms (Jeon et al., 2019). The currently recognized drugs are three acetylcholinesterase inhibitors (AChEIs) and one N-Methyl-D-Asparate (NMDA) receptor antagonist. Of note, NMDA receptor antagonist is not approved for mild AD. According to Tan et al., AChEIs have benefits for stabilizing or slowing decline in cognition, function, behavior and the clinical global change of patients with AD, however more dropouts and adverse events occurred with AChEIs compared to placebo (Tan et al., 2014). In contrast, previous studies reported no difference from placebo groups about 6 months after the initiation of AChEIs (Wolfson et al., 2002; Farlow et al., 2008; Winblad et al., 2006). Recently, aducanumab, a new monoclonal antibody targeting aggregated beta-amyloid, was approved by the FDA. However, its clinical efficacy is uncertain because it is unclear whether or not reducing amyloid-βs clinically useful. Moreover, about 40% of the patients in clinical trials experienced vasogenic edema and cortical microhemorrhages, adverse events called amyloid-related...
imaging abnormalities. The initial price set by the manufacturer was prohibitively high (Rabinovici, 2021). Therefore, new therapeutic agents are essential.

Because traditional East Asian medicine has since ancient times been used to treat symptoms of what appears to be dementia, researchers are now turning to traditional medicines to identify potential neuroprotective or disease-modifying agents (Suzuki et al., 2005; Kaushik et al., 2018; Lim et al., 2018; Jeon et al., 2019; Watari et al., 2019). Traditional Chinese Medicine was introduced to Japan between the 5th and 6th centuries and has changed to suit Japanese needs over time to what is now called Kampo medicine. Kampo medicines have been approved by the Ministry of Health, Labor and Welfare of Japan for the treatment of the various diseases seen in specialty departments, and many doctors routinely prescribe Kampo medicine in clinical practice.

Hachimijiogan (HJG) is a traditional Japanese (herbal) medicine (Kampo) that is prescribed for the treatment of “kidney™ deficiency,” a key pathology of Kampo medicine. (Terasawa, 1993). It is effective for various symptoms common to the older population, such as low back pain, nocturia, numbness, and coldness in the legs. This study was done because we consider one of the mechanisms of cognitive impairment, from the Kampo medicine perspective, to be “kidney™ deficiency.” Hachimijiogan is composed of eight herbal components, for which five crude drugs (Rehmannia Root, Cornus Fruit, Dioscorea Rhizome, Moutan Bark and Cinnamon Bark) and their extracted ingredients have been reported to have efficacy against AD pathology (Jeon et al., 2019). There has only been one clinical study on HJG for dementia. According to Iwasaki, et al., HJG was effective for moderate to severe dementia (AD combined with cerebrovascular disease), but the results were not conclusive because of the small number of cases (Iwasaki et al., 2004). Our previous study demonstrated that HJG administration ameliorated memory impairment in rats treated with amyloid-beta protein and cerebral ischemia (Moriyama et al., 2017). Further, we found in a basic experiment that HJG has a neurotrophic effect and ameliorated the cognitive impairment of AD model rats via cAMP response element binding protein (CREB) activation (Kubota et al., 2017).

Based on our experience and our previous studies, this study was done to test our hypothesis that HJG would be safe and effective for the treatment of patients with mild AD.

Materials and methods

Study drug

We used TSUMURA hachimijiogan Extract Granules for Ethical Use (TJ-7, HJG, lot number P04531, Tokyo Japan). HJG is manufactured in compliance with Japanese good manufacturing practice (GMP) defined by Japanese law to ensure quality control. HJG is made by mixing the botanical drugs described below, followed by extraction using a hot water, and finally the extract is made into a powder by spray drying method. Its quality has been ascertained through quantification of the amounts of marker ingredients (paeonilflorin, loganin, benzoylmesaconine, and 14-anisoylaconine). The daily dose of HJG extract (7.5 g) includes dried botanical drugs in the following amounts: Japanese Pharmacopoeia [JP] Rehmannia Root (6.0 g), JP Cornus Fruit (3.0 g), JP Dioscorea Rhizome (3.0 g), JP Alisma Rhizome (3.0 g), JP Poria Sclerotium (3.0 g), JP Moutan Bark (2.5 g), JP Cinnamon Bark (1.0 g), and JP Powdered Processed Aconite Root (0.5 g) (The Ministry of Health, Labour, and Welfare, Japan, 2022). The detailed information on botanical drugs is provided in the Supplementary material. HJG was administered orally with warm water before a meal.

Ethics

The study was conducted in accordance with the principles of the Declaration of Helsinki and Tokyo and approved by the Kyushu University Hospital Clinical Research Review Board (CRB) (Fukuoka, Japan) (CRB approval number: KD 2019001). We received written informed consent from all participants.

Study design

This 24-week, open-label, randomized, multicenter trial was conducted at 14 sites in Japan between 2 August 2019 and 31 March 2022. We initially planned to recruit participants at three institutes according to the published protocol (Kainuma et al., 2020). However, because of the COVID-19 pandemic, the recruitment was delayed, so from January 2021 we were able to add 11 institutes. Our protocol was, in brief, that patients with mild AD were divided into an AChEI plus HJG group and an AChEI alone group to compare the effectiveness and safety of the addition of HJG. Patients diagnosed with AD were eligible if they met all the inclusion criteria. The main inclusion criteria were 1) age ≥50 to <85 years, 2) mild AD with a score on the Mini Mental State Examination (MMSE) of ≥21 points, 3) taking the same dosage of AChEI (Donepezil, Galantamine, or Rivastigmine) for more than 3 months, but not taking NMDA receptor antagonist (Memantine). The exclusion criteria were as follows. 1) A change of medication dose that could affect the worsening of dementia during the past 3 months, 2) Kidney dysfunction (eGFR <30 ml/min/1.73 m²), 3) AST or ALT >100 IU/L, 4) At least one complication with gastric ulcer, bronchial asthma, or epilepsy, 5) Taking Kampo Medicine other than HJG for more than the past 3 months, 6) patients determined to be...
ineligible for study by their doctors for reasons such as disease with serious complications.

**Outcome**

The primary outcome was the change of the Alzheimer’s Disease Assessment Scale Cognitive Component- Japanese Version (ADAS-Jcog) from baseline to 6 months. The secondary outcome was the change from baseline to 6 months of the Instrumental Activity of Daily Life (IADL), the Apathy scale, and the Neuropsychiatric Inventory (NPI)-Q.

The safety outcomes included spontaneously reported adverse events (AEs) or serious AEs (SAEs).

**Randomization and masking**

All participants met the eligibility criteria and gave written informed consent. Randomization was done with the Randomization Module of Research Electronic Data Capture (RED Cap). A computer-generated list of random numbers was transferred to RED Cap for block randomization by age and sex, then the participants were randomly assigned at a 1:1 ratio. Participants, physicians, and data evaluators were aware of the allocation group after randomization, but outcome evaluators were blinded.

**Procedure**

After randomization, the HJG group took 2.5 g of HJG extract 3 times/day in addition to AChEI for 6 months and the control group continued to take only AChEI. Patients underwent assessments at baseline and after 3 and 6 months. AEs, or SAEs, vital signs (temperature, heart rate, and blood pressure), and physical examination and laboratory tests were evaluated each visit.

**Statistical analysis**

SAS® software (version 9.4; SAS Institute Japan Ltd., Tokyo, Japan) was used for all statistical analyses.

An efficacy analysis was done on the per protocol sets (PPS), with the same analysis of the full analysis sets (FAS) done for sensitivity analysis to confirm the accuracy of the results. From all subjects, FAS will exclude cases of serious noncompliance with clinical research methods, cases not administered, and cases not observed (complete absence of the primary outcome). A group consisting of subjects who are included in the FAS and do not meet the following conditions is defined as a PPS. 1) Subjects who do not meet the selection criteria specified in the protocol or who violate the exclusion criteria. 2) Significant deviations from the study protocol. 3) Subjects who failed to receive adequate doses of the study drug (medication compliance rate <75%). To analyze the primary outcome, an analysis of covariance was done for the change in ADAS-Jcog from baseline for the PPS, with treatment group and baseline values as covariates. Continuous variables are expressed as the mean value and standard deviation. The analysis of secondary outcomes was also done in the same way as the analysis of the primary outcome of the PPS. For statistical analyses, a two-tailed test at the 10% level of significance was done. Two-tailed interval estimation was done with a 90% confidence interval (CI) and corresponding p values (with significance defined as p < 0.10).

The data of any participant who received even one medication was eligible for the Safety Analysis Set (SAS) evaluation, with the number and incidence of liver dysfunction, interstitial pneumonia, and gastrointestinal disorders calculated for both groups.

**Results**

The first patient was enrolled on 5 September 2019 and the last patient completed the study on 24 March 2022: 77 patients were enrolled and randomly assigned.

No difference was found in the background factors of the HJG and Control groups (Table 1). From among the 77 enrollles, the data of 69 (34 HJG and 35 control) were available for analysis (Figure 1). In the analysis of ADAS-Jcog, the difference in the change from baseline at 6 months of the HJG and control groups was 1.29 (90% CI, -0.74 to 3.32, p = 0.293). The difference at 3 months was 1.98 (90% CI, -0.17 to 4.14, p = 0.130) (Figure 2). Furthermore, in the subgroup analysis by sex, the differences from baseline to 3 and 6 months for male participants were -0.23 (90% CI, -2.61 to 2.16, p = 0.873) and -0.66 (90% CI, -3.30 to 1.97, p = 0.671), respectively (Figure 3A).

In contrast, the differences in change from baseline to 3 and 6 months for female participants were 3.70 (90% CI, 0.50 to 6.91, p = 0.059) and 2.90 (90% CI, 0.09 to 5.71, p = 0.090), respectively (Figure 3B). For age, the differences in the change from baseline to 3 and 6 months for participants ≥65 years were 2.35 (90% CI, 0.01 to 4.68, p = 0.099) and 1.47 (90% CI, -0.71 to 3.66, p = 0.265), respectively (Figure 4A), and the differences for participants <65 years were -2.18 (90% CI, -6.35 to 1.99, p = 0.307) and -0.79 (90% CI, -2.82 to 1.24, p = 0.427), respectively (Figure 4B). No significant difference in education was found.

In the analysis of IADL, the differences between the HJG and control groups in the change from baseline to 3 and 6 months for male participants were 0.33 (90% CI, -0.07 to 0.72, p = 0.170) and 0.38 (90% CI, -0.31 to 1.08, p = 0.352), respectively. For the female participants they were 0.48 (90% CI, -0.10 to 1.07, p = 0.168) and 0.37 (90% CI, -0.40 to 1.15, p = 0.425), respectively.
In the analysis of the apathy scale, the differences between the HJG and control groups in the change from baseline to 3 and 6 months were 1.46 (90% CI, −0.67 to 3.58; p = 0.256) and 0.19 (90% CI, −1.60 to 1.99; p = 0.858), respectively.

In the analysis of NPI-Q, the differences between the HJG and control groups in the change from baseline to 3 and 6 months were −1.51 (90% CI, −4.01 to 0.99; p = 0.317) and −0.89 (90% CI, −3.07 to 1.29; p = 0.497), respectively.

With FAS, the same results were gained for the primary and secondary points. In the HJG group, only one participant discontinued, because of interstitial pneumonia and liver dysfunction.

### Discussion

This exploratory study was the first to investigate the effectiveness and safety of adding HJG to AChEI for the treatment of the cognitive impairment of patients with mild AD.

Our results (Figure 2) showed that the ADAS-Jcog worsened over time in the control group, in which the participants continued to receive AChEI alone, whereas the group that received HJG had delayed cognitive deterioration for 6 months, although the difference was not significant. Analysis by sex showed that the women in the HJG group showed more significant improvement in cognitive function at both 3 and 6 months than the women in the control group who received AChEI alone. (Figure 3B). For the participants over 65 years, at 3 months a more significant improvement in cognitive function was seen in the HJG group compared with the control group (Figure 4A). HJG has proven effective for various age-related diseases, and our results showing effectiveness for participants over 65 years-of-age indicate that cognitive dysfunction may be a symptom of "kidney deficiency.” Our data support HJG as being effective for older patients with mild cognitive dysfunction.

In our analysis of the ADAS-Jcog as a whole and of women only, the HJG group tended to have improvement in cognitive function at 3 months, but deterioration was observed at 6 months. AChEI has been reported to improve cognitive function after 3–6 months of treatment, but a decline was seen after 9 months of treatment (Farlow M et al., 2000; 2022).

### TABLE 1 Baseline characteristics.

|                          | HJG group(n = 39) | Control group(n = 35) |
|--------------------------|-------------------|-----------------------|
| Sex(male/female)         | 15/24             | 15/20                 |
| Age (years)              | 75 ± 6.6 (73–77)  | 76 ± 7.1 (74–78)      |
| Height (cm)              | 157 ± 9.2 (154–160) | 157 ± 7.8 (155–160)  |
| Body weight (kg)         | 55 ± 11 (52–59)   | 54 ± 11 (50–57)       |
| Body mass index (kg/m²)  | 22 ± 3.5 (21–23)  | 22 ± 3.2 (20–23)      |
| RUN (mg/dL)              | 16 ± 4.3 (15–18)  | 17 ± 5.2 (16–19)      |
| Creatinine (mg/dL)       | 0.80 ± 0.21 (0.73–0.87) | 0.79 ± 0.26 (0.70–0.88) |
| eGFR (mL/min/1.73m²)     | 64 ± 17 (58–69)   | 67 ± 18 (60–73)       |
| Albumin (g/dL)           | 4.1 ± 0.3 (4.0–4.2) | 4.1 ± 0.3 (4.1–4.2)  |
| HbA1c (%)                | 6.0 ± 1.0 (5.7–6.3) | 6.1 ± 1.0 (5.8–6.4)  |
| Systolic Hypertension (mmHg) | 131 ± 18 (126–137) | 132 ± 17 (127–138)   |
| Diastolic Hypertension (mmHg) | 76 ± 13 (72–80)   | 79 ± 11 (75–82)       |
| Disease duration, years  | 3.6 ± 2.8 (2.7–4.5) | 2.7 ± 2.2 (2.0–3.4)  |
| Education (university/non university) | 12/27 | 6/29 |
| ADAS-Jcog                | 14 ± 5.2 (13–16)  | 14 ± 5.6 (13–16)      |
| IADL                     | 5.2 ± 2.5 (4.4–6.0) | 4.9 ± 2.2 (4.1–5.7)  |
| NPI-Q score              | 5.6 ± 7.7 (3.1–8.1) | 4.4 ± 8.5 (1.5–7.3)  |
| Apathy scale             | 14 ± 7.0 (11–16)  | 14 ± 6.5 (12–17)      |
| Hypertension, n(%)       | 15(39%)           | 17(45%)               |
| Dyslipidemia, n(%)       | 11(28%)           | 13(36%)               |
| Diabetes mellitus, n(%)  | 7(18%)            | 6(16%)                |
| Old brain infarction, n(%) | 1(3%)       | 0(0%)                |
| AChE inhibitor           |                  |                       |
| Donepezil                | 20 (51%)          | 24 (69%)              |
| Galantamine              | 11 (28%)          | 7 (20%)               |
| Rivastigmine             | 8 (21%)           | 4 (11%)               |
FIGURE 1
Enrollment, Randomization, and Trial completion.

FIGURE 2
Difference between the HJG and control groups in the change from baseline to 3 and 6 months: ADAS-Jcog.
Winblad B et al., (2006). Nine patients (2 HJG, 7 Control) in our study were enrolled immediately after AChEI for 3 months, which may have resulted in a synergistic effect of HJG and AChEI at the 3 months point. However, at 6 months, 9 months after the start of AChEI administration, the effect would be that of HJG alone. To examine the hypothesis, we did a post-hoc statistical analysis, and the difference in the change of ADAS-Jcog from baseline to 3 and 6 months of the HJG and control groups was 2.25 (90% CI, −0.19 to 4.70 p = 0.129), and 0.87 (90% CI, −1.31 to 3.04 p = 0.509), respectively. From these results, excepting the patients recruited immediately after 3 months administration of AChEI, the group difference was increased at 3 months, although the difference was not significant.

The present study design included three points of change in ADAS-Jcog as the minimum clinically important differences (MCID), in reference to previous studies (Department of Health and Human Services et al., 1989; Schrag et al., 2012), but no clinical study of aducanumab or other antibody drugs that have been done in recent years on patients with mild AD have shown MCID in ADAS-Jcog exceeding 2 points (Doody et al., 2014; Honig et al., 2018; US Food and Drug Administration., 2020; Mintun et al., 2021), and no consensus has been reached on MCID in ADAS-Jcog (Rockwood et al., 2010; Liu et al., 2021). We also set the MCID at 3 points, but this number is the minimum amount of change for an individual subject and may have been overstated for the MCID of the ADAS-Jcog in our participants with mild AD. However, the difference between the two groups in the study of women was 2.90 at 6 months. Slitzer B et al. reported a group
difference on ADAS-cog of 2.3 at 24 weeks for donepezil and placebo groups with Early-stage AD (Seltzer et al., 2004). Further, a solanezumab trial of mild dementia due to AD reported a difference of ~0.80 at 80 weeks (Honig et al., 2018). With donanemab for early AD the difference was -1.86 at 76 weeks (Mintun et al., 2021). Although the primary outcome point of these two studies was over 24 weeks, the figures of these two studies show group differences that were obviously lower than ours. These data suggest that HJG may have been related to the improvement of cognitive function when compared to the rate of change in recent clinical studies on mild AD.

Only one patient in the HJG group had to drop out of the study, because of interstitial pneumonia. It is important to note that this patient had lung disease at the start of the study. This indicates that risk from the administration of HJG is very low and that it is safe to use. Although our results were not conclusive, they do show that HJG is safe and effective for clinical use and that its clinical use would benefit patients with mild AD.

The present study also showed that AChEI was effective for some male patients. The patients in the final PPS analysis of the HJG group included 21 women and 13 men, resulting in a lack of statistical power and a statistically insignificant difference. In our protocol, the eligibility criteria were set based on the assumption that fixing the AChEI dose for more than 3 months would reduce the number of dropouts due to side effects caused by AChEI. In future study it will be important to verify the efficacy of HJG by examining a larger number of patients for more than 6 months after taking AChEIs.

The Apathy Score is used to assess motivation in the cerebrovascular disease sequelae, but it is well known that, with regard to AD, depression may be present or it may be optimistic with no disease awareness in its early stages. No significant difference was found in a donepezil group compared to controls in a study of early AD that used the Apathy scale (Seltzer et al., 2004).

Donepezil has been reported to improve the instrumental and basic ADLs of moderate to severe AD patients (Feldman et al., 2006). However, we could not find reports in which Donepezil was effective for early AD. According to previous studies, as the severity of AD progresses, ADL decreases and the burden on caregivers increases (Sun et al., 2018; Kawaharada et al., 2019). The severity of behavioral disorders and cognitive, psychological, and motor impairment of patients with AD have been positively correlated with increasing levels of caregiver burden of distress (Raggi et al., 2015). In this study, we used the NPI-Q score to assess caregiver burden; however, it was done with mild AD patients, and no difference between the groups was found in apathy score or IADL, which would indicate no difference in the burden of caregiving.

There are several limitations in the present study. The sample size available for analysis was small, especially that of men. Also, it was not placebo-controlled and was done over a relatively short-term period. Studies including a long-term treatment protocol and better-balanced samples will be necessary to verify the current results.

Conclusion

Although our data are not conclusive, they indicate that HJG has an adjuvant effect for acetylcholinesterase inhibitors and that it is effective for delaying the cognitive dysfunction commonly seen in mild Alzheimer’s disease patients.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the Kyushu University Hospital Clinical Research Review Board (CRB) (CRB approval number: KD 2019001). The patients/participants provided their written informed consent to participate in this study.

Author contributions

Conceptualization: MK, SO, K-IY, TO, AY, MM, and YT. Investigation: SO, SK, OI, K-IY, TO, SH, SS, TH, SH, MY, AY, SS, MH, K-IW, DS, KH, NS, HS, YK, YM, and YT. Project administration: MK. Methodology: KF, and MM. Monitor: SY. Writing-original draft: MK, Writing-review and editing: KF, SO, MM, and YT.

Funding

This study was supported by a grant from the Japan Agency for Medical Research and Development (AMED) (grant number: JP19lk0310056).

Acknowledgments

We also deeply thank Kiyoko Momota, Kyoko Okada, and Wakako Hiraoka for their efforts and support for our study.
Conflict of interest

MK received a research grant from Tsumura that is not related to this study. Tsumura and Co. (Tokyo, Japan) provided TSMURA hachimijiogan (TJ-7) Extract Granules for Ethical Use free of charge.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Cipriani, G., Danti, S., Picchi, L., Nuti, A., and Foirino, M. D. (2020). Daily functioning and dementia. Dement. Neurocogn. 14, 93–102. doi:10.1590/1980- 57642020n14-020001

Department of Health and Human Services; Public Health Service; Food and Drug Administration; US Food and Drug Administration (1989). Peripheral and central nervous system drugs advisory committee meeting. Rockville,MD,USA.

Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 311–321. doi:10.1056/NEJMoia132889

Farlow, M., Anand, R., Messina, J., Jr, Hartman, R., and Veach, J. (2000). A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur. Neurol. 44, 236–241. doi:10.1159/000089243

Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Emir, B., Mastey, V., et al. (2006). Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J. Am. Geriatr. Soc. 51, 737–744. doi:10.1111/j.1532-5415.2006.00512.x

Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., et al. (2018). Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330. doi:10.1056/NEJMoa1701971

Iwasaki, K., Kobayashi, S., Chimura, Y., Taguchi, M., Inoue, K., Cho, S., et al. (2004). A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine “ba wei di huang wan” in the treatment of dementia. J. Am. Geriatr. Soc. 52, 1518–1521. doi:10.1111/j.1532-5415.2004.52415.x

Jeon, S. G., Song, E. J., Lee, D., Park, J., Nam, Y., Kim, J. I., et al. (2019). Traditional oriental medicines and Alzheimer’s disease. Aging Dis. 10, 307–328. doi:10.14336/ AD.2018.0328

Kainuma, M., Funakoshi, K., Ouma, S., Yamashita, K. I., Ohara, T., Yoshiawa, A., et al. (2020). The efficacy and safety of hachimijiogan for mild Alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial: A study protocol. Med. Baltim. 580, e22370. doi:10.1097/MD. 00000000000022370

Kaushik, R., Morkovin, E., Schneeberg, J., Confetttura, A. D., Kreutz, M. R., Senkov, O., et al. (2018). Traditional Japanese herbal medicine yokukansan targets distinct but overlapping mechanisms in aged mice and in the SxEAD mouse model of Alzheimer’s disease. Front. Aging Neurosci. 10, 411. doi:10.3389/ fnagi.2018.00411

Kawaharada, R., Sugimoto, T., Matsuda, N., Tsuibo, Y., Sakurai, T., and One, R. (2019). Impact of loss of independence in basic activities of daily living on caregiver burden in patients with Alzheimer’s disease: A retrospective cohort study. Geriatr. Gerontol. Int. 19, 1243–1247. doi:10.1111/ ggi.13803

Kubota, K., Fukue, H., Sato, H., Hashimoto, K., Fujikane, A., Moriyama, H., et al. (2017). The traditional Japanese herbal medicine hachimijiogan elicits neurite outgrowth effects in PC12 cells and improves cognitive in AD model rats via phosphorylation of CREB. Front. Pharmacol. 8, 850. doi:10.3389/fphar.2017. 00850

Lim, H. S., Kim, Y. J., Sohn, E., Yoon, J., Kim, B. Y., and Jeong, S. J. (2018). Bosunjuk-tang, a traditional herbal formula, exerts neuroprotective effects and ameliorates memory impairments in Alzheimer’s disease-like experimental models. Nutrients 10, 1952. doi:10.3390/nu10121952

Liu, K. Y., Schneider, L. S., and Howard, R. (2021). The need to show minimum clinically important differences in Alzheimer’s disease trials. Lancet. Psychiatry 8, 1013–1016. doi:10.1016/S2215-6584(21)00197-8

McDade, E., and Bateman, R. J. (2017). Stop Alzheimer’s before it starts. Nature 54, 153–155. doi:10.1038/nature20153

Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardaryfo, P. A., Andersen, S. W., et al. (2021). Donanemab in early Alzheimer’s disease. N. Engl. J. Med. 384, 1691–1704. doi:10.1056/NEJMoai2010708

Moriyama, H., Mishima, T., Kainuma, M., Watanebe, T., Nagao, M., Takasaki, K., et al. (2017). Effect of hachimijiogan on memory impairment induced by beta- amyloid combined with cerebral ischemia in rats. Traditional Kampo Med. 4, 51–54. doi:10.1002/tkm2.1069

Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., and Brayne, C. (2014). Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. Lancet Neurol. 13, 788–794. doi:10.1016/S1474-4422(14)70136-X

Rabinovici, G. D. (2021). Controversy and progress in Alzheimer’s disease - FDA approval of aducanumab. N. Engl. J. Med. 385, 771–774. doi:10.1056/ NEJMp2111320

Raggi, A., Tasca, D., Panerai, S., Neri, V., and Ferri, R. (2015). The burden of distress and related coping processes in family caregivers of patients with Alzheimer’s disease living in the community. J. Neurol. Sci. 358, 77–81. doi:10.1016/j.jns.2015.08.024

Rockwood, K., Fay, S., and Gorman, M. (2010). The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer’s disease. Int. J. Geriatr. Psychiatry 25, 191–201. doi:10.1002/gps.2319

Schrarg, A., and Schott, J. M. Alzheimer’s Disease Neuroimaging Initiative (2012). What is the clinically relevant change on the ADAS-Cog? J. Neurol. Neurosurg. Psychiatry 83, 171–173. doi:10.1136/jnnp-2011-300881

Seltzer, B., Zolnouni, P., Nunex, M., Goldman, R., Kumar, D., Jeni, J., et al. (2004). Efficacy of donepezil in early-stage alzheimer disease: A randomized placebo-controlled trial. Arch. Neurol. 61, 1852–1856. doi:10.1001/archneur.61.12.1852

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the national institute on aging-alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 280–292. doi:10.1016/j.jalz.2011.03.003

Sun, M., Mainland, B. J., Ornstein, T. J., Mallya, S., Fococo, A. J., Sin, G. L., et al. (2018). The association between cognitive fluctuations and activities of daily living and quality of life among institutionalized patients with dementia. Int. J. Geriatr. Psychiatry 33, e280–e285. doi:10.1002/gps.4788

Suzuki, T., Futami, S., Igari, Y., Matsuura, N., Watanebe, K., Nakano, H., et al. (2005). A Chinese herbal medicine, cho-tsu-san, improves cognitive function and activities of daily living of patients with dementia: A double-blind, randomized, placebo-controlled study. J. Am. Geriatr. Soc. 53, 2238–2240. doi:10.1111/j.1532- 5415.2005.00412_7.x

Tan, C. C., Yu, J. T., Wang, H. F., Tan, M. S., Meng, X. F., Wang, C., et al. (2014). Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. J. Alzheimers Dis. 41, 615–631. doi:10.3233/JAD- 132490

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Terasawa, K. (1993). *Kampo, Japanese oriental medicine*. Tokyo: KK Standard McIntyre.

The Ministry of Health Labour and Welfare (2022). The Japanese 18th edition English Version. Tokyo. Available at: https://www.mhlw.go.jp/content/11120000/000912390.pdf (Accessed June 10, 2022).

US Food and Drug Administration (2020). Combined FDA and biogen briefing information for the November 6, 2020 meeting of the peripheral and central nervous system drugs advisory committee. Published online Nov 6. Available at: https://www.fda.gov/media/143502/download (Accessed May 25, 2022).

Watari, H., Shimada, Y., Matsui, M., and Tohda, C. (2019). Kihito, a traditional Japanese Kampo medicine, improves cognitive function in Alzheimer’s disease patients. *Evid. Based. Complement. Altern. Med.* 2019, 4086749. doi:10.1155/2019/4086749

Winblad, B., Wimo, A., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., et al. (2006). 3-year study of donepezil therapy in Alzheimer’s disease: Effects of early and continuous therapy. *Dement. Geriatr. Cogn. Disord.* 21, 353–363. doi:10.1159/000091790

Wolfson, C., Oremus, M., Shukla, V., Momoli, F., Demers, L., Ferrault, A., et al. (2002). Donepezil and rivastigmine in the treatment of Alzheimer’s disease: A best-evidence synthesis of the published data on their efficacy and cost-effectiveness. *Clin. Ther.* 24, 862–886. doi:10.1016/s0149-2918(02)80004-2

World health Organization. (2018). Available at: https://www.who.int/news-room/fact-sheets/detail/dementia (Accessed June 12, 2022).